Compare AWX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWX | ENSC |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.2M |
| IPO Year | 1998 | 2017 |
| Metric | AWX | ENSC |
|---|---|---|
| Price | $2.82 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.08 |
| AVG Volume (30 Days) | 9.9K | ★ 278.3K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.24 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,090,000.00 | $5,066,650.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $2.43 | $0.23 |
| 52 Week High | $2.93 | $2.16 |
| Indicator | AWX | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 62.45 | 49.44 |
| Support Level | $2.49 | $0.39 |
| Resistance Level | $2.89 | $0.44 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 83.75 | 66.38 |
Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment, which is the key revenue driver, provides hazardous and non-hazardous brokerage and management services to industrial, commercial, municipal, and governmental customers, captive landfill management for an industrial customer, and saltwater injection well operations. Its Golf and related operations segment consists of four golf courses and associated clubhouses, which provide dining and banquet facilities, a hotel which provides lodging and resort-related amenities.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.